GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Immunic Inc (STU:10VA) » Definitions » Shiller PE Ratio

Immunic (STU:10VA) Shiller PE Ratio : (As of Jun. 04, 2024)


View and export this data going back to 2015. Start your Free Trial

What is Immunic Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Immunic Shiller PE Ratio Historical Data

The historical data trend for Immunic's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Immunic Shiller PE Ratio Chart

Immunic Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Immunic Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Immunic's Shiller PE Ratio

For the Biotechnology subindustry, Immunic's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Immunic's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Immunic's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Immunic's Shiller PE Ratio falls into.



Immunic Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Immunic's E10 for the quarter that ended in Mar. 2024 is calculated as:

For example, Immunic's adjusted earnings per share data for the three months ended in Mar. 2024 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=-0.276/131.7762*131.7762
=-0.276

Current CPI (Mar. 2024) = 131.7762.

Immunic Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201406 -26.790 100.560 -35.106
201409 -18.314 100.428 -24.031
201412 -19.140 99.070 -25.459
201503 -22.915 99.621 -30.311
201506 -22.453 100.684 -29.387
201509 -18.176 100.392 -23.858
201512 -12.485 99.792 -16.486
201603 -11.135 100.470 -14.605
201606 -10.680 101.688 -13.840
201609 -11.405 101.861 -14.754
201612 -14.030 101.863 -18.150
201703 -14.586 102.862 -18.686
201706 -10.324 103.349 -13.164
201709 -10.068 104.136 -12.740
201712 -11.830 104.011 -14.988
201803 -11.030 105.290 -13.805
201806 -10.272 106.317 -12.732
201809 -9.598 106.507 -11.875
201812 -2.110 105.998 -2.623
201903 -4.505 107.251 -5.535
201906 -1.345 108.070 -1.640
201909 -0.745 108.329 -0.906
201912 -0.504 108.420 -0.613
202003 -0.715 108.902 -0.865
202006 -0.799 108.767 -0.968
202009 -0.594 109.815 -0.713
202012 -0.378 109.897 -0.453
202103 -1.369 111.754 -1.614
202106 -0.681 114.631 -0.783
202109 -0.646 115.734 -0.736
202112 -0.531 117.630 -0.595
202203 -0.672 121.301 -0.730
202206 -0.681 125.017 -0.718
202209 -0.697 125.227 -0.733
202212 -1.529 125.222 -1.609
202303 -0.542 127.348 -0.561
202306 -0.498 128.729 -0.510
202309 -0.478 129.860 -0.485
202312 -0.440 129.419 -0.448
202403 -0.276 131.776 -0.276

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Immunic  (STU:10VA) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Immunic Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Immunic's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Immunic (STU:10VA) Business Description

Traded in Other Exchanges
Address
1200 Avenue of the Americas, Suite 200, New York, NY, USA, 10036
Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing three small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function.

Immunic (STU:10VA) Headlines

No Headlines